Therapies
Friday, May 17th, 2013
Circulation: May 14, 2013 Background—Onset-to-reperfusion time has been reported to be associated with clinical prognosis. However, its impact on mortality remained to be assessed. Using a collaborative pooled analysis, we examined whether early mortality after successful endovascular treatment is time dependent. Methods and Results—In a collaborative pooled analysis of 7 endovascular databases, we assessed the impact […]
Therapies
Friday, May 17th, 2013
JAMA Neurology: May 13, 2013 Importance Studies comparing the efficacy of intra-arterial therapy (IAT) and medical therapy in reducing final infarct volume (FIV) in intracranial large-vessel occlusions (ILVOs) are lacking. Objectives To assess whether patients with ILVOs who received IAT have smaller FIVs than patients who received either intravenous tissue plasminogen activator therapy (IVT) or no reperfusion therapy […]
Therapies
Friday, May 17th, 2013
Metapress: April 23, 2013 Abstract Central post-stroke pain syndrome (CPSP) is a debilitating sequel that can follow thalamic sensory stroke. Less well recognized, CPSP follows lateral medullary stroke and parietal cortical stroke and may develop anywhere along the spinothalamic or trigemino-thalamic pathways. Patients describe sharp, stabbing, or burning pain and experience hyperpathia and especially allodynia. […]
Therapies
Saturday, May 11th, 2013
Nature Reviews Neurology: May 7, 2013 This Review focuses on the application of telemedicine to the care of patients with acute stroke (telestroke), from the prehospital setting through hospitalization. Telestroke has grown remarkably in the past decade and has entered mainstream care for patients with acute stroke. Telestroke enables such patients to be remotely evaluated, […]
Therapies
Saturday, May 11th, 2013
J NeuroIntervent Surgery: May 4, 2013 Abstract Background Infectious intracranial aneurysms (IIAs) are rare and potentially devastating. First-line management involves intravenous antibiotics, with surgical or endovascular management reserved for cases of failed medical treatment or aneurysmal rupture. Endovascular therapy has become the primary approach for treating these small, distally located aneurysms. Liquid embolic agents are well […]
Therapies
Saturday, May 11th, 2013
J NeuroIntervent Surgery: May 4, 2013 Abstract Aims To evaluate the efficacy and safety of mechanical thrombectomy with the Solitaire FR device in revascularization of patients with acute basilar artery occlusion (ABAO) and to identify the predictive factors for clinical outcome. Methods This prospective single-center study included 31 patients with acute ischemic stroke attributable to ABAO treated […]
Therapies
Saturday, May 11th, 2013
Lancet Neurology: May 2 2013 Background Many international guidelines on the prevention of venous thromboembolism recommend targeting heparin treatment at patients with stroke who have a high risk of venous thrombotic events or a low risk of haemorrhagic events. We sought to identify reliable methods to target anticoagulant treatment and so improve the chance of […]
Therapies
Saturday, May 11th, 2013
Mayo Clinic Proceedings: May 1, 2013 Abstract Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug Administration approval of new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, clinicians now have a broader choice. Read more
Therapies
Thursday, May 2nd, 2013
STROKEAHA: April 30, 2013 Background and Purpose—In-hospital stroke (IHS) differs from out-of-hospital stroke (OHS) in risk factors and outcomes. We compared IHS and OHS treated with thrombolysis from a large national cohort in a cross-sectional study to further clarify these differences. Methods—The Nationwide Inpatient Sample for the years 2005–2010 was searched for adult acute ischemic stroke […]
Therapies
Thursday, May 2nd, 2013
FDA: April 29, 2013 The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding. Plasma is the only other product approved for this use in the United States. Patients receiving chronic anticoagulation therapy with warfarin and other […]
